ABL Diagnostics (FR001400AHX6 – ABLD), a leading Euronext-listed company in the development of molecular biology assays and software for microbiology laboratories, has announced the official appointment of the company and its exclusive distributor, Laborama Co. Ltd., to provide Next Generation Sequencing (“NGS”) solutions to the National Laboratory for Public Health (NLPH) in Lithuania.
No responses yet